Italian journal of dermatology and venereology · 2026
T2-Reg: a regional web registry on Th2-mediated diseases.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
D'Onghia Martina, Rubegni Giovanni, Manzo Margiotta Flavia, Calabrese Laura, Lo Conte Sofia, Magliulo Manfredi, Montesi Giulio, Mandalà Marco, Salerni Lorenzo, Tosi Gianmarco, Cameli Paolo, Cuccia Aldo, Gori Alessia, Magnano Michela, Pescitelli Leonardo, Antiga Emiliano, Milanesi Nicola, Vispi Martina, Peccianti Camilla, Gola Massimo, Mazzatenta Carlo, Lazzeri Laura, Romanelli Marco, Pimpinelli Nicola, Rubegni Pietro, Cartocci Alessandra
Аннотация
BACKGROUND: Systemic type 2 inflammation, driven by T helper 2 (Th2)-type immune responses, is central to allergic inflammatory diseases, including atopic dermatitis, allergic rhinitis, asthma, nasal polyposis, and food allergy. These conditions frequently coexist and share common immunological mechanisms. The objective of this study is to describe the design and development of T2-Reg, a regional registry for Th2-mediated diseases, aimed at collecting real-life data to improve patient management and research.
METHODS: This multicentric retrospective and prospective observational study has been conducted through an electronic web registry. Ethical approval was obtained (N° 22045). Patients with atopic dermatitis, allergic asthma, or allergic rhinitis have been enrolled from dermatology, pulmonology, and otolaryngology units across multiple hospitals in Tuscany, Italy. Data have been collected via REDCap, ensuring security and compliance with GDPR. The registry includes demographic, clinical, and laboratory data, treatment history, and disease-specific clinometric scores.
RESULTS: From June 2022 to December 2024, 619 patients were enrolled, with an equal gender distribution and diverse educational backgrounds. Atopic comorbidities were present in 73% of cases, with allergic rhinitis being the most common. Disease severity indices and treatment history were recorded, including systemic and biologic therapies.
CONCLUSIONS: T2-Reg serves as a valuable tool for tracking disease progression, treatment outcomes, and comorbidities. Its integration with AI and interoperability with national and international registries enhances research potential. Despite some limitations, such as data entry burden and missing information, T2-Reg contributes to personalized medicine and public health initiatives in atopic diseases.
METHODS: This multicentric retrospective and prospective observational study has been conducted through an electronic web registry. Ethical approval was obtained (N° 22045). Patients with atopic dermatitis, allergic asthma, or allergic rhinitis have been enrolled from dermatology, pulmonology, and otolaryngology units across multiple hospitals in Tuscany, Italy. Data have been collected via REDCap, ensuring security and compliance with GDPR. The registry includes demographic, clinical, and laboratory data, treatment history, and disease-specific clinometric scores.
RESULTS: From June 2022 to December 2024, 619 patients were enrolled, with an equal gender distribution and diverse educational backgrounds. Atopic comorbidities were present in 73% of cases, with allergic rhinitis being the most common. Disease severity indices and treatment history were recorded, including systemic and biologic therapies.
CONCLUSIONS: T2-Reg serves as a valuable tool for tracking disease progression, treatment outcomes, and comorbidities. Its integration with AI and interoperability with national and international registries enhances research potential. Despite some limitations, such as data entry burden and missing information, T2-Reg contributes to personalized medicine and public health initiatives in atopic diseases.